GRAIL is a healthcare company dedicated to the early detection of cancer, aiming to change the landscape of cancer care by developing advanced technologies that enable the identification of multiple cancer types at an early stage when treatment is most effective. Utilizing next-generation sequencing, population-scale clinical studies, and cutting-edge data science, GRAIL's research focuses on enhancing the understanding of cancer biology, with the ultimate goal of delivering a multi-cancer early detection blood test. Headquartered in Menlo Park, California, and supported by a network of locations including Washington, D.C., North Carolina, and the United Kingdom, GRAIL operates with a multidisciplinary team of scientists, engineers, and physicians. The company values innovation, collaboration, and excellence, striving to alleviate the global burden of cancer through its pioneering work in early detection technology.